GALDY Stock Analysis: GALDERMA | NYSE
Drug Manufacturers - Specialty & Generic | NYSE, USA | Market Cap: 45.857m USD | 12M Return: 16.5% | US36321W1053 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 8.59M
Rev. Trend: 97.7%
Warnings
Tailwinds
No distinct edge detected
Seasonality 2.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Galderma Group AG is a Switzerland-based dermatology company headquartered in Zug, founded in 1981. It offers a science-driven portfolio spanning injectable aesthetics, dermatological skincare, and therapeutic dermatology, with flagship brands including Dysport, Restylane, Sculptra, Cetaphil, ALASTIN, and Soolantra. The company serves the global dermatology market through both prescription and consumer skincare products.
As a large-cap healthcare company, Galderma operates in the specialty dermatology segment, combining aesthetic medical treatments (such as neuromodulators and dermal fillers) with over-the-counter skincare and prescription therapeutics. The dermatology specialty space is characterized by strong consumer brand loyalty in skincare categories and recurring demand from aesthetic procedures, supporting a diversified revenue mix across elective and medical channels.
- Relfydess neurotoxin launch intensifies competition with Botox aesthetics
- NEMLUVIO approval drives therapeutic dermatology revenue growth
- Cetaphil skincare sales expand amid dermatology consumer demand
| Net Income: 613.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 6.01 > 1.0 |
| NWC/Revenue: 7.29% < 20% (prev 7.09%; Δ 0.19% < -1%) |
| CFO/TA 0.09 > 3% & CFO 1.19b > Net Income 613.0m |
| Net Debt (-632.0m) to EBITDA (1.20b): -0.53 < 3 |
| Current Ratio: 1.19 > 1.5 & < 3 |
| Outstanding Shares: last quarter (234.6m) vs 12m ago -1.26% < -2% |
| Gross Margin: 68.86% > 18% (prev 69.48%; Δ -0.62% > 0.5%) |
| Asset Turnover: 40.30% > 50% (prev 35.19%; Δ 5.11% > 0%) |
| Interest Coverage Ratio: 5.01 > 6 (EBIT TTM 876.0m / Interest Expense TTM 175.0m) |
| A: 0.03 (Total Current Assets 2.44b - Total Current Liabilities 2.06b) / Total Assets 13.4b |
| B: 0.47 (Retained Earnings 6.35b / Total Assets 13.4b) |
| C: 0.07 (EBIT TTM 876.0m / Avg Total Assets 13.0b) |
| D: 1.55 (Book Value of Equity 8.15b / Total Liabilities 5.24b) |
| Altman-Z'' = 3.82 = AA |
| DSRI: 1.00 (Receivables 893.0m/754.0m, Revenue 5.24b/4.44b) |
| GMI: 1.01 (GM 69.48% / 68.86%) |
| AQI: 0.94 (AQ_t 0.76 / AQ_t-1 0.81) |
| SGI: 1.18 (Revenue 5.24b / 4.44b) |
| TATA: -0.04 (NI 613.0m - CFO 1.19b) / TA 13.4b) |
| Beneish M = -2.92 (Cap -4..+1) = A |
As of September 27, 2026, the stock is trading at USD 39.45 with a total of 16,836 shares traded. Over the past week, the price has changed by +2.49%, over one month by -7.91%, over three months by -10.80% and over the past year by +16.52%.
Current recommended Stop Loss: 37.50 (which is 4.9% or 1.9 ATR below the current price).
GALDERMA has no consensus analysts rating.
P/E Trailing = 53.1487
P/E Forward = 29.9401
P/S = 7.7421
P/B = 5.5139
P/EG = 1.166
Revenue TTM = 5.24b USD
EBIT TTM = 876.0m USD
EBITDA TTM = 1.20b USD
Long Term Debt = 2.58b USD (from longTermDebt, last quarter)
Short Term Debt = 27.0m USD (from shortLongTermDebt, last quarter)
Debt = 148.0m USD (Leases only: 148.0m)
Net Debt = -632.0m USD (calculated: Debt 148.0m - CCE 780.0m)
Enterprise Value = 45.2b USD (45.9b + Debt 148.0m - CCE 780.0m)
Interest Coverage Ratio = 5.01 (Ebit TTM 876.0m / Interest Expense TTM 175.0m)
EV/FCF = 43.86x (Enterprise Value 45.2b / FCF TTM 1.03b)
FCF Yield = 2.28% (FCF TTM 1.03b / Enterprise Value 45.2b)
FCF Margin = 19.67% (FCF TTM 1.03b / Revenue TTM 5.24b)
Net Margin = 11.70% (Net Income TTM 613.0m / Revenue TTM 5.24b)
Gross Margin = 68.86% ((Revenue TTM 5.24b - Cost of Revenue TTM 1.63b) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 3.38 (Enterprise Value 45.2b / Total Assets 13.4b)
Interest Expense / Debt = 118.2% (Interest Expense 175.0m / Debt 148.0m)
Taxrate = 4.08% (26.0m / 638.0m)
NOPAT = 840.3m (EBIT 876.0m * (1 - 4.08%))
Current Ratio = 1.19 (Total Current Assets 2.44b / Total Current Liabilities 2.06b)
Debt / Equity = 0.02 (Debt 148.0m / totalStockholderEquity, last quarter 8.15b)
Debt / EBITDA = -0.53 (Net Debt -632.0m / EBITDA 1.20b)
Debt / FCF = -0.61 (Net Debt -632.0m / FCF TTM 1.03b)
Total Stockholder Equity = 7.83b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.71% (Net Income 613.0m / Total Assets 13.4b)
RoE = 7.83% (Net Income TTM 613.0m / Total Stockholder Equity 7.83b)
RoCE = 8.42% (EBIT 876.0m / Capital Employed (Equity 7.83b + L.T.Debt 2.58b))
RoIC = 7.59% (NOPAT 840.3m / Invested Capital 11.1b)
WACC = 9.19% (E(45.9b)/V(46.0b) * Re(9.22%) + (debt cost/tax rate unavailable))
Discount Rate = 9.22% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -89.32 | Cagr: -1.26%
[DCF] Terminal Value 75.30% ; FCFF base≈703.8m ; Y1≈806.8m ; Y5≈1.19b
[DCF] Fair Price = 13.89 (EV 15.6b - Net Debt -632.0m = Equity 16.2b / Shares 1.17b; r=9.19% [WACC]; 5y FCF grow 15.0% → 2.50% )
Revenue Correlation: 97.74 | Revenue CAGR: 12.83% | SUE: N/A | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=3.51 | Chg30d=-2.64% | Revisions=-25% | GrowthEPS=+0.0% | GrowthRev=+22.9%
EPS next Year (2027-12-31): EPS=5.16 | Chg30d=-3.06% | Revisions=-25% | GrowthEPS=+47.2% | GrowthRev=+18.3%